Patients with secondary rectal cancer after prostate cancer radiation therapy may have worse survival ... They were less likely to receive any neoadjuvant treatment (51.6% vs 94.4%) or surgery ...

Jeffrey Wong, MD, discusses the evolving field of combination therapy with radiopharmaceuticals in prostate cancer. In an interview with Targeted Oncology TM, Jeffrey Wong, MD, radiation oncologist ...

On March 28, the FDA approved Pluvicto for adults with PSMA-positive metastatic castration-resistant prostate cancer who have received androgen receptor pathway inhibitor therapy and are ...

A multimodal treatment approach, incorporating local surgical intervention and neoadjuvant systemic therapy (NT), has been explored to improve survival in patients with locally advanced PCa and ...

Objective: Boennuokang ® leuprorelin acetate microspheres show a certain efficacy in patients with prostate cancer, but its utilization as neoadjuvant therapy in patients with high-risk prostate ...

The management of locally advanced prostate cancer ... neoadjuvant systemic therapy targeted to alternative molecular pathways (including parmiparib, cisplatin, tislelizumab or docetaxel, respectively ...

Among patients with intermediate-risk prostate cancer, treatment with external-beam radiation therapy (EBRT) with or without six months of neoadjuvant-deprivation-therapy (NADT) showed a high prostate ...

Examples of ovarian suppression drugs that have been approved by the US Food and Drug Administration (FDA) are goserelin ... sensitive breast cancer: neoadjuvant therapy, adjuvant therapy ...

Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for ... including Lupron ...

ORGOVYX (relugolix) is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. If you are a HCP in the ... particularly concerning androgen deprivation therapy ...